Volume | 919,538 |
|
|||||
News | - | ||||||
Day High | 33.35 | Low High |
|||||
Day Low | 32.76 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Perrigo Company Plc Ireland | PRGO | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
33.11 | 32.76 | 33.35 | 33.06 | 32.90 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
16,333 | 919,538 | US$ 33.09 | US$ 30,427,422 | - | 25.77 - 40.28 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:10:00 | 149,165 | US$ 33.06 | USD |
Perrigo Company Plc Ireland Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.48B | 135.52M | - | 4.66B | -12.7M | -0.09 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Perrigo Company Plc Irel... News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PRGO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 31.45 | 33.35 | 31.13 | 32.43 | 1,272,676 | 1.61 | 5.12% |
1 Month | 30.99 | 33.35 | 29.79 | 31.25 | 1,213,915 | 2.07 | 6.68% |
3 Months | 31.81 | 33.35 | 25.77 | 29.67 | 1,997,950 | 1.25 | 3.93% |
6 Months | 28.17 | 34.60 | 25.77 | 30.28 | 1,852,145 | 4.89 | 17.36% |
1 Year | 37.48 | 40.28 | 25.77 | 31.80 | 1,594,046 | -4.42 | -11.79% |
3 Years | 41.73 | 51.09 | 25.77 | 36.82 | 1,478,676 | -8.67 | -20.78% |
5 Years | 48.70 | 65.10 | 25.77 | 40.86 | 1,330,341 | -15.64 | -32.11% |
Perrigo Company Plc Irel... Description
Perrigo Co PLC is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company's product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessation aids. In addition to private label manufacturing, the company also sells products under its own brands (largely in the skincare and oral-care category). The company became a pure-play in OTC consumer healthcare in 2021, following a series of divestitures over several years (sold off generic prescription topicals, animal health, and active pharmaceutical ingredient business). In late 2021, Perrigo signed an offer to acquire HRA Pharma. |